A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Palmoplantaris Pustulosis

Interventions

DRUG

Placebo

Placebo, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4

DRUG

CNTO 1959

CNTO 1959 200 mg, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4

Trial Locations (8)

Asahikawa

Fukuoka

Fukushima

Matsumoto

Sapporo

Sendai

Tokyo

Touon